ReVenG: This study is assessing the effectiveness of re-treatment with a combination of targeted therapy drugs in people with recurring chronic lymphocytic leukaemia who have previously had treatmentA Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients With Recurring Chronic Lymphocytic Leukemia

Summary

This study is recruiting people with chronic lymphocytic leukaemia who have had prior treatment with venetoclax targeted therapy in combination with an anti-CD20 antibody, with or without another therapy. Eligible participants must have achieved a document response to their first-line therapy treatment to be eligible. Participants will be assigned to one of two experimental cohorts. Participants in both cohorts will receive combination targeted therapy that consists of intravenous (IV) obinutuzumab plus oral venetoclax (VenG). This will be given in 28-day cycles for a total of 6 cycles per cohort. Following this, all participants will receive venetoclax alone. Those in Cohort 1 will receive 6 cycles of venetoclax alone. Those in Cohort 2 will receive 18 cycles of venetoclax alone.

Treatment Type

Systemic therapy (chemotherapy, hormone therapy or immunotherapy)